Table 1.

Summary of Clinical and Laboratory Features of Patients With Common Variable Immunodeficiency and Outcome of Vaccination

CVID patient number	Sex	Age	Years since diagnosis	Lymphocyte counts	Lymphocyte subsets	Comorbidities	Latest serum immunoglobulin assessmenta	Type of vaccine	Preimmunization anti–SARS-CoV-2 (antispike) antibodies	Postimmunization anti–SARS-CoV-2 (antispike) antibodies	Adverse effects after first vaccine dose	Adverse effects after second vaccine dose
1	F	58	9	Normal	Normal	Obesity, hypertension, thyroid nodule	IgG, 832 mg/dL IgA, 6 mg/dL IgM, 9 mg/dL	Pfizer-BioNTech	Absent	8.68 BAU/mL	Pain at injection site, diffuse myalgias, headache, fatigue	Pain at injection site
2	F	54	19	Normal	Normal	None	IgG, 777 mg/dL IgA, 2 mg/dL IgM, 2 mg/dL	Moderna	Absent	812.90 BAU/mL	Pain at injection site	Low-grade fever, myalgias, headache, fatigue
3	F	63	1	Mild lymphopenia (1060/μL)	Normal	Celiac disease, osteoporosis with vertebral fractures	IgG, 665 mg/dL IgA, 14 mg/dL IgM, 6 mg/dL	Pfizer-BioNTech	Absent	212.7 BAU/mL	Pain at injection site	Pain at injection site
4	M	45	12	Normal	Normal	None	IgG, 721 mg/dL IgA, 3 mg/dL IgM, 2 mg/dL	Pfizer-BioNTech	160 BAU/mL	10185 BAU/mL	Headache	Pain at injection site
5	F	37	6	Normal	CD19 B cells <1%b	Bronchiectasis, liver nodular lymphoid hyperplasia	IgG, 515 mg/dL IgA, 2 mg/dL IgM, 1 mg/dL	Pfizer-BioNTech	Absent	Absent	Pain at injection site, headache, myalgias, chills	Pain at injection site

Abbreviations: BAU, binding arbitrary unit, according to the World Health Organization international standard (<1, negative; >1, positive); CVID, common variable immunodeficiency; ECLIA, electrochemiluminescence immunoassay; F, female; Ig, immunoglobulin; M, male.

NOTE. Antibodies were detected by ECLIA.

^aNormal values for serum immunoglobulin isotypes were as follows: IgG, 700 to 1600 mg/dL; IgA, 70 to 400 mg/dL; IgM, 40 to 230 mg/dL.

^bNormal B-cell frequencies: 6% to 20%.